DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - Seite 2

“At DBV, we look forward to a day when allergists and families of children with peanut allergy have multiple approved treatment options and together decide on the best therapy for each child’s situation,” continued Dr. Mohideen. “DBV, is committed to generating robust, long-term safety data with Viaskin Peanut to aid in future shared decision-making. To that end, our ongoing clinical programs evaluating Viaskin Peanut in children ages 4-7 and toddlers ages 1-3 will each comprise approximately 600 patients in the active treatment arms.”

“As part of a collaboration with Icahn School of Medicine at Mount Sinai and Beckman Coulter Life Sciences, basophil activation testing, a blood test also known as BAT, was conducted on over 100 Viaskin Peanut participants aged 1-3 years, who were enrolled in DBV’s Phase 3 EPITOPE trial,” continued Dr. Mohideen. “This novel form of BAT, streamlined by Beckman Coulter to be more easily implemented at clinical sites, was used to help understand the immune modifying effects of epicutaneous immunotherapy over time. This could help advance our understanding of BAT as a potential treatment monitoring tool.”

DBV Abstract Details:

Oral Abstract Presentation

“A Streamlined Approach to Basophil Activation Testing for Longitudinal Characterization of Toddlers with Peanut Allergy During a Multi-Site Phase 3 Double-Blind Placebo-Controlled Trial of Epicutaneous Immunotherapy (EPIT)” will be presented by Dr. Jean-Marc Busnel (Beckman Coulter)

• Presentation date: Saturday, February 24, 2024
• Presentation time: 2:15 p.m. – 2:25 p.m. ET
• Presentation location: Convention Center, Level 3, Ballroom B
  
  

Poster Presentation

“Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study” will be presented by Dr. David Fleischer, Associate Professor of Pediatrics at Children’s Hospital Colorado.

• Poster number: 379
• Session title: Treatment and Management of IgE-mediated Food Allergy
• Presentation date: Saturday, February 24, 2024
• Presentation time: 9:45 a.m. – 10:45 a.m. ET
• Presentation location: Convention Center, Level 2, Hall D
  
  

About DBV Technologies
DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).